Table 4.
Estimated impacts of SP at baseline on health outcomesa
| Model | LV1 | LV2 | LV1 + RE | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Coef. | SE | Coef. | SE | Coef. | SE | ||||
| Health outcome (the higher, the better) | |||||||||
| Mental health | |||||||||
| MH1 (range: 1–5) | 0.016 | (0.015) | 0.041 | (0.021) | 0.014 | (0.015) | |||
| MH2 (range: 10–70) | 0.820 | *** | (0.199) | 1.187 | *** | (0.307) | 0.776 | *** | (0.204) |
| Self-rated health (SRH) (range: 1–5) | 0.018 | (0.035) | 0.090 | (0.053) | 0.032 | (0.036) | |||
| Activities of Daily Livings (ADL) | |||||||||
| BADL (range: 6–24) | 0.147 | *** | (0.043) | 0.021 | (0.065) | 0.158 | *** | (0.043) | |
| IADL (range: 5–20) | 0.159 | *** | (0.035) | 0.019 | (0.054) | 0.166 | *** | (0.036) | |
| Onset of disease | |||||||||
| Hypertension or dyslipidaemia | −0.001 | (0.001) | 0.001 | (0.001) | −0.000 | (0.001) | |||
| Diabetes or high blood sugar | 0.003 | (0.004) | 0.001 | (0.006) | 0.003 | (0.004) | |||
| Heart attack or Stroke | 0.003 | (0.005) | 0.012 | (0.008) | 0.002 | (0.005) | |||
| Cancer or malignant tumour | 0.004 | * | (0.001) | 0.001 | (0.002) | 0.003 | * | (0.002) | |
| Emotional, nervous, psychiatric problems or memory-related disease | 0.001 | (0.002) | −0.002 | (0.004) | 0.000 | (0.003) | |||
| Stomach or digestive disease | −0.004 | (0.005) | −0.004 | (0.008) | −0.004 | (0.005) | |||
| Other diseases | −0.012 | (0.007) | 0.003 | (0.010) | −0.014 | * | (0.007) | ||
Note: a Controlled for one-wave-lagged (for LV1 and LV1 + RE) or two-lagged (for LV2) wave-lagged health outcome, as well as covariates
***p < 0.001, **p < 0.01, *p < 0.05